钠-葡萄糖共转运蛋白2抑制剂在心脏重塑中作用机制的研究进展  

Research progress on effect of sodium glucose co-transporter 2 inhibitors in cardiac remodeling

作　　者：赵冰冰 史宏涛[2] ZHAO Bing-bing;SHI Hong-tao(The First Clinical Medical College of Shanxi Medical University,Taiyuan 030001,China;Cardiovascular disease department,The First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一临床医学院,山西省太原市030001 [2]山西医科大学第一医院心血管内科

出　　处：《中国心血管病研究》2024年第6期510-516,共7页Chinese Journal of Cardiovascular Research

基　　金：国家自然科学基金青年科学基金项目(82100406)。

摘　　要：心脏重塑是各类心血管疾病主要的病理生理基础,被定义为心脏受损伤后引发的一系列基因组表达、分子、细胞、间质的改变造成心脏形态及功能的变化,也是最终导致心力衰竭的重要原因。最新研究表明,钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)对改善心血管疾病具有应用前景,预防和逆转不良重塑可能是发挥心血管益处的机制之一。因此,本文就SGLT2i改善心脏重塑的作用机制、相关临床试验、不良反应、局限性以及未来的发展方向做一综述,为预防或治疗心血管疾病提供理论依据和临床指导。Cardiac remodeling is the main pathophysiological basis of various cardiovascular diseases.It encompasses genomic expression,molecular,cellular,and mesenchymal changes caused by heart injury that lead to changes in heart shape and function,and is also an important cause of heart failure.Recent research shows that sodium glucose cotransporter 2(SGLT2)inhibitors have dramatic cardiovascular benefits,and prevention and reversal of adverse cardiac remodeling may be one of them.Therefore,this article reviews the mechanism of SGLT2 inhibitors improving cardiac remodeling,related clinical trials,adverse reactions,limitations and future development,in order to provide theoretical basis and clinical guidance for the prevention or treatment of cardiovascular diseases.

关 键 词：钠-葡萄糖共转运蛋白2抑制剂 心脏重塑 心血管疾病 

分 类 号：R54[医药卫生—心血管疾病]